Topline data were announced from a phase 3 trial evaluating orforglipron in adults with obesity or overweight with weight-related comorbidities.

Eli Lilly and Company (NYSE: LLY) is one of the Good Stocks to Invest in Now. On August 7, Eli Lilly and Company (NYSE:LLY) ...

Here are five oral obesity candidates that, according to Mizuho’s Graig Suvannavejh, could change the weight loss game.

A transformative moment in the global fight against obesity has emerged with the announcement of positive topline results ...

Orforglipron led to 11.5% placebo-adjusted weight loss at 72 weeks (among those who adhered to high-dose treatment) in Attain-1, versus 13.9% at 64 weeks in Oasis 4 for the 25-mg dose of oral ...

Significant news last week included Vertex Pharmaceuticals dropping development of its acute pain candidate VX-993 following ...

TheStreet. Stocks had a nifty week last week, especially technology shares. All of the major averages had solid weeks. The ...

China’s drugmakers are racing to roll out cheaper or more innovative alternatives. Read more at straitstimes.com. Read more ...

A legacy ranch in Jackson Hole, WY, has come onto the market, with records showing it is owned by former Eli Lilly exec Dr.

The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed ...

Ozempic, the diabetes drug, induced drastic weight loss and reduced the risk of heart attacks in obese people. It became a ...

Eli Lilly's pill, orforglipron, is a step closer to becoming the first needle-free alternative in the booming market for weight loss drugs.